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Abstract: Introduction: Major histocompatibility complex class II genes are considered major
genetic risk factors for autoimmune diabetes. We analysed Human Leukocyte Antigen (HLA)
DR and DQ haplotypes in a cohort with early-onset (age < 5 years), long term type 1 diabetes
(T1D) and explored their influence on clinical and laboratory parameters. Methods: Intermediate
resolution HLA-DRB1, DQA1 and DQB1 typing was performed in 233 samples from the
German Paediatric Diabetes Biobank and compared with a local control cohort of 19,544 cases.
Clinical follow-up data of 195 patients (diabetes duration 14.2 ± 2.9 years) and residual C-peptide
levels were compared between three HLA risk groups using multiple linear regression analysis.
Results: Genetic variability was low, 44.6% (104/233) of early-onset T1D patients carried the
highest-risk genotype HLA-DRB1*03:01-DQA1*05:01-DQB1*02:01/DRB1*04-DQA1*03:01-DQB1*03:02
(HLA-DRB1*04 denoting 04:01/02/04/05), and 231 of 233 individuals carried at least one of six risk
haplotypes. Comparing clinical data between the highest (n = 83), moderate (n = 106) and low risk
(n = 6) genotypes, we found no difference in age at diagnosis (mean age 2.8 ± 1.1 vs. 2.8 ± 1.2 vs.
3.2 ± 1.5 years), metabolic control, or frequency of associated autoimmune diseases between HLA
risk groups (each p > 0.05). Residual C-peptide was detectable in 23.5% and C-peptide levels in
the highest-risk group were comparable to levels in moderate to high risk genotypes. Conclusion:
Genes 2017, 8, 146; doi:10.3390/genes8050146 www.mdpi.com/journal/genes
Genes 2017, 8, 146 2 of 17
In this study, we saw no evidence for a different clinical course of early-onset T1D based on the HLA
genotype within the first ten years after manifestation.
Keywords: MHC II; C-peptide; autoimmunity; human leukocyte antigen; diabetes mellitus
1. Introduction
Nowadays, approximately 25–30% of type 1 diabetes (T1D) patients are younger than five years at
the time of diagnosis and epidemiological studies reported a continuous rise in the incidence, particularly
in preschool children [1–5]. Exposure to genetic, immunological, as well as environmental factors play
an important role in disease etiology, but the underlying mechanisms are largely unknown [6].
Although T1D is not a classic inherited disease, and about 80% of T1D manifestations
occur in persons without a positive family history for T1D, the individual genetic background is
an important factor in the autoimmune process. Genome-wide association studies revealed that
approximately half of the genetic risk for T1D is conferred by the genomic region harbouring the
major histocompatibility complex (MHC) class II genes, primarily Human Leukocyte Antigen (HLA)
DRB1, DQA1, and DQB1 [7–9]. These genes are encoding cell surface glycoproteins, presenting intra-
or extracellular peptides, and play a role in orchestrating the T-cell mediated autoimmune destruction
of the pancreatic β-cells [10,11]. While MHC class I molecules are present on virtually all nucleated
cells, MHC class II molecules are expressed on B-cells, dendritic cells, macrophages and activated
T-cells [6,11]. Both protective alleles and alleles conferring susceptibility have been described for the
genes in the DQ and DR region of the HLA complex. The empirical risk for T1D may be estimated
based on family history, and susceptible or protective HLA genes to vary between 0.01% for individuals
with no positive family history and protective HLA alleles, and 30–70% for individuals with an affected
sibling or twin, positive for high-risk HLA genes [6]. HLA risk alleles are not only associated with
a higher risk but also with an earlier onset of diabetes [12–14].
Several studies in European-descent populations have addressed the frequency of high-risk
alleles, including the highest-risk heterozygous genotype HLA-DRB1*03:01-DQA1*05:01-DQB1*02:01/
DRB1*04-DQA1*03:01-DQB1*03:02 (HLA-DRB1*04 summarizing the HLA-DRB1*04:01/02/04/05 alleles),
in children younger than six years at the time of T1D diagnosis [9,13–16]. Even without a positive
family history, these children have an increased lifetime risk of about 5% to develop autoimmune
diabetes [17]. The risk increases further to up to 40% with a positive family history for diabetes.
The prevalence of HLA alleles is highly variable, depending on the ethnic background. HLA class
I alleles, e.g., A*24, and B*39, also contribute to the diabetes risk [18]. In adulthood, besides HLA
genes, other genes gain relevance. Genome-wide association analyses of adult-onset T1D yielded more
than 50 non-HLA genes, such as PTPN22, STAT4, CTLA4, IL2RA, INS, ERBB3, SH2B3 and CLEC16A
associated with islet autoimmunity [19,20].
The aim of our study was to examine the HLA-DR and DQ haplotypes in more than 200 clinically
well-characterized children with early-onset diabetes (manifestation before the age of five years) from
the German Pediatric Diabetes Biobank with regard to the presence of high-risk HLA genotypes.
As the impact of HLA genes on clinical parameters in T1D in follow-up is largely unknown [21,22],
we focused on the influence of HLA haplotypes on clinical and laboratory parameters. We aimed to
analyse whether high-risk HLA alleles lead to a more severe phenotype.
2. Materials and Methods
2.1. Study Population
A nationwide, population-based cohort study, called the ‘Clinical Course of Type 1 Diabetes in
Children, Adolescents, and Young Adults with Disease Onset in Preschool Age’ study, was initiated
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in 2009 as part of the German Competence Network on Diabetes Mellitus and integrated into the
German Center for Diabetes Research (DZD) as of January 2015 [23]. The study included patients with
manifestation before the age of five years between 1993 and 1999, and at least 10 years of diabetes
duration. All included patients were diagnosed with T1D by their physicians based on clinical and
laboratory parameters.
2.2. Inclusion Criteria
Participants were invited by telephone interview to provide biosamples and a random group of 261
individuals donated samples (DNA, plasma, and serum) to the German Pediatric Diabetes Biobank at the
German Competence Network/German Diabetes Center, Düsseldorf, Germany. Complete HLA-typing
was successful in 233 samples, baseline clinical data (sex, age, migration background) were available for
223 patients, and used for description of clinical data, while conjoined clinical datasets with HLA were
available for 195 patients and included in the analysis of the HLA impact on clinical data.
The study was conducted following the principles expressed in the Declaration of Helsinki and
approved by the Ethics Committee of the Heinrich Heine University, Düsseldorf (internal study
numbers 3431 and 5800). The DPV registry (diabetes prospective follow up, Diabetes Patienten
Verlaufsdokumentation) has the ethical approval at the University of Ulm plus local data safety approval.
2.3. Variable Assessment
Longitudinal anthropometric (weight, height, body mass index (BMI)), clinical (lipid profile,
creatinine, urine albuminuria, blood pressure), and diabetes-related data (frequency of self-monitoring
of blood glucose (SMBG), total daily insulin dose, daily insulin dose per kg body weight, insulin therapy
(conventional therapy (CT), i.e., ≤3 daily injections; multiple daily injections (MDI), i.e., ≥4 daily
injections; continuous subcutaneous insulin infusion (CSII), pump therapy), glycated haemoglobin
(HbA1c), events of severe hypoglycaemia or hypoglycaemic coma, hypoglycaemia or diabetic
ketoacidosis-related hospitalization and diabetes-related autoimmune disease (thyroiditis, coeliac
disease) after diabetes onset were retrospectively obtained from the German/Austrian nationwide DPV
registry [24] for the period of 1993–2014 by pseudonymous linkage. 16 out of 223 T1D patients had
a migration background (Slovakia, Morocco, Sweden, UK, USA, Poland, Kazakhstan, Russia, Greece,
Argentina, Pakistan, Afghanistan, Croatia and Romania (each one patient) and Turkey (two patients)).
The 195 clinically well-characterized patients had an average observation period of 12.1 ± 4.3 years
(median 13 years, interquartile range (IQR) 9; 17 years) and on average 4.8 ± 1.9 visits with their
local diabetes center per year (median 4, IQR 3.5; 6 visits). For each patient, all available data for
continuous or ordinal variables were averaged (median) and the number of events of hypoglycaemia
or diabetic ketoacidosis were summed up stratified by year of diabetes duration during the follow-up
time. Presence of long-term diabetic complications and diabetes-associated autoimmune diseases
was assumed in patients if the respective condition was documented at least at one visit during the
total individual follow-up time. Standard deviation scores of BMI (BMI-SDS) were determined using
German reference data (KIGGS, German Health Interview and Examination Survey for Children and
Adolescents [25]) by applying the Lambda-Mu-Sigma (LMS) method [26]. To adjust for between-center
variation owing to different laboratory methods, HbA1c measurements were standardized to the
Diabetes Control and Complication Trial (DCCT) reference range (4.05–6.05%, 20–42 mmol/mol) using
the multiple-of-the-mean method as described previously [24].
2.4. Control Population
HLA antigen frequencies of a large regional control population recruited from a centre in North
Rhine-Westphalia, Germany, were retrospectively derived from 19,544 randomly selected samples
from the Bone Marrow Donor Registry Düsseldorf. As self-reported ethnicity was not available for
registry donors, those cases with a known migration background could not be excluded from the
control population. The ethnic background of the control and patient group can be expected to be
Genes 2017, 8, 146 4 of 17
comparable. Thus, we decided to include T1D patients with a known migration background in the
analysis in order to maintain a comparable ethnic background. Registry donors underwent HLA
typing at the Institute for Transplantation Diagnostics and Cell Therapeutics (ITZ) at the University
Hospital Düsseldorf as described below.
2.5. Human Leukocyte Antigen Typing
Genomic DNA was extracted from blood samples and purified using QIAamp DNA Blood
Midi Kit (Qiagen, Hilden, Germany). HLA-typing was performed in an American Society
for Histocompatibility and Immunogenetics (AHSI) accredited laboratory at the Institute for
Transplantation Diagnostics and Cell Therapeutics (ITZ) at the University Hospital Düsseldorf.
High resolution HLA-typing of the donors in the Bone Marrow Donor Registry Düsseldorf was
performed by sequencing-based typing (SBT) of each second exon, as described previously [27].
Complete HLA-DRB1-DQA1-DQB1 intermediate-resolution typing was performed in 233 DNA
specimens from the German Pediatric Diabetes Biobank without changes in setup. HLA-typing
of the patients’ samples was performed using the LabType SSO (One Lambda, Kanoga Park,
CA, USA) with Luminex technology [28], according to the manufacturer’s protocol. In this test,
the second (and third in cases of DQ) exon is amplified and analysed. The intermediate typing results
which did not belong to the Common and Well Defined Alleles (CWD) group were excluded [29].
Allele Combinations were assessed in the IPD-IMGT/HLA database (Version 3.25.0, accessible
online at http://www.ebi.ac.uk/ipd/imgt/hla/ [30]). The HLA-DRB1-DQA1-DQB1 haplotypes were
determined by comparison of the phenotype with well-known haplotype frequencies [31]. The two
haplotypes with the highest product of the haplotype frequencies were selected from all possible
haplotype combinations in each case. Calculations were performed using an in-house developed
computer program (Visual Basic.NET). In ambiguous alleles such as DQB1*02:01 and 02:02, that were
indistinguishable in the SBT-typed controls, we derived the allele from the haplotype combination
using this approach. HLA-DRB1*14:01 and 14:54 and DQA1*04:01 and 04:02 were indistinguishable by
intermediate resolution typing and are therefore listed as ambiguous alleles.
2.6. Neonatal Diabetes Genes
Sanger sequencing of the most common neonatal diabetes genes (ABCC8, KCNJ11, INS) was
performed for the eight patients who developed diabetes before the age of 12 months, as previously
described [32].
2.7. C-peptide
C-peptide in biobank serum specimens was analysed using the Mercodia Ultrasensitive
enzyme-linked immuno-sorbent assay (ELISA, Mercodia, Uppsala, Sweden, detection limit 2.5 pmol/L)
at the Institute of Clinical Diabetology, Düsseldorf, according to the manufacturer’s protocol
(intra-assay coefficient of variation (CV) 1.5%, inter-assay CV 2.9%), as described previously [33].
2.8. Statistics
For a simple description of the patients and specific analyses (diabetic complications, associated
autoimmune disorders) only the aggregated data of the last documented year of diabetes duration
were used, while for further analyses the entire longitudinal dataset was used. For descriptive analysis,
mean (standard deviation, SD), median (interquartile range, IQR), and percentages for categorical
variables were calculated. Event rates of severe hypoglycaemia, hypoglycaemic coma, hyperglycaemia,
or ketoacidosis-associated hospitalization were analysed assuming a Poisson distribution. Continuous
and categorical variables were compared between groups by the Wilcoxon test or the χ2-(expected
number of cases > 5 in each group) or Fisher’s exact test. Additionally, odds ratios were estimated
for comparisons of haplotype and genotype frequencies. Multivariable mixed linear (continuous
outcome), mixed Poisson (rate outcome) or fixed-effects logistic regression (binary outcome with
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last year of observation) were applied to adjust for covariates in comparison analyses. Within the
regression analyses, F-tests (linear and Poisson regression) or χ2-tests (logistic regression) were used to
test for statistical significance. Results from regression analyses are presented as adjusted means, event
rates per 100 patient years, or percentages, including IQR and respective p-values. In all analyses, we
did not adjust for multiple testing. p-values of two-sided tests < 0.05 were considered statistically
significant. Statistical analyses were performed with the statistical software package SAS for Windows,
version 9.4 (SAS Institute Inc., Cary, NC, USA) and Graph Pad Prism 7 (GraphPad Software, La Jolla,
CA USA) using Baptista Pike method for estimation of CIs for odds ratios.
3. Results
3.1. Patient Characteristics
Mean age at onset of T1D was 2.8 ± 1.2 years (median 2.8, IQR 1.7; 3.8 years) and mean diabetes
duration at the last documented year was 14.2 ± 2.9 years (median 15.0, IQR 13.1; 16.1 years).
Males represented 55.2% of the population. The mean HbA1c within the patient group was 8.0 ± 1.4%
(64 ± 15 mmol/mol) (median 7.9, IQR 7.1; 8.7%; median 83, IQR 54; 72 mmol/mol). The cohort
included 16 (7.2%) patients with a migration background. For insulin administration 48.9% of patients
used CSII (continuous subcutaneous insulin infusion), 45.7% used multiple daily injections (MDI),
and 5.4% used less than three daily injections (CT).
We analysed the most relevant common neonatal diabetes genes (KCNJ11, ABCC8, INS) to exclude
monogenic diabetes in infancy-onset diabetes (n = 8 patients with manifestation before age 12 months).
No pathogenic mutations were identified.
3.2. Comparison of Human Leukocyte Antigen Haplotypes between the Study Group and the Control Population
3.2.1. Prevalence of Human Leukocyte Antigen Haplotype Combinations
The heterozygous haplotype combination HLA-DRB1*03:01-DQA1*05:01-DQB1*02:01/DRB1*04-
DQA1*03:01-DQB1*03:02 (DRB1*04 combining the DRB1*04:01/02/04/05 alleles) was the most prevalent
genotype and found in 44.6% of the early-onset diabetes subjects (n = 104/233, Figure 1). This haplotype
combination is named the ‘highest-risk’ genotype. Within the control group the frequency of this
haplotype combination was 1.8% (n = 343/19,544), resulting in an odds ratio of 45.14 (34.14; 96.99,
p < 0.001) for the highest-risk genotype in early-onset T1D compared to controls.
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3.2.2. Prevalence of HLA Haplotypes
Frequencies of the DR-DQ haplotypes were compared between the early-onset T1D cohort
and a regional control population (Table 1). Significant susceptibility for T1D was associated with
DRB1*03:01-DQA1*05:01-DQB1*02:01 (DR3-DQ2), DRB1*04-DQA1*03:01-DQB1*03:02 (DR4-DQ8), and the
rare haplotype DRB1*04:05-DQA1*03:01-DQB1*02:02, as well as DRB1*08:01-DQA1*04:01/02-DQB1*04:02
(DR8-DQ4).
Altogether, 221 out of 233 (94.8%) patients carried at least one of the two main high-risk HLA
haplotypes, also abbreviated as DRB1*03 or DRB1*04. While 124 patients exhibited combinations of
these, heterozygous (n = 104) or homozygous (n = 20, including two cases with a regular DR4 high-risk
haplotype in combination with DRB1*04:05-DQA1*03:01-DQB1*02:02), 97 patients had one of these
two high-risk haplotypes (‘moderate risk’) and only 12 cases (5.2%) did not show either one (‘low
risk’).
We separately analysed the second alleles within 97 heterozygous cases showing one
high-risk haplotype, DRB1*03 (DR3-DQ2) or DRB1*04 (DR4-DQ8), evaluating the haplotype on
the other chromosome (Table ??) and compared with heterozygous controls. Of note potentially
protective alleles were missing, even in the second alleles. Genetic heterogeneity was low
and most of the second heterozygous alleles were neutral and shared between the two groups.
Additional susceptibility was conveyed by DRB1*01:01-DQA1*01:01-DQB1*05:01 and DRB1*08:01-
DQA1*04:01/02-DQB1*04:02 (see above) in both groups, as well as DRB1*16:01-DQA1*01:02-
DQB1*05:02 and less frequently DRB1*09:01-DQA1*03:02-DQB1*03:03 in the DRB1*03/x group, while
DRB1*13:02-DQA1*01:02-DQB1*06:04 just failed significance in the DRB1*04/x group.
Investigating the third group of 12 cases, which did not show either DR3-DQ2 or DR4-DQ8,
the abovementioned five haplotypes were present in 9 of 12 cases. One patient showed
DRB1*04:08-DQA1*03:01-DQB1*03:04, which shares the crucial alanine at position 57 of the DQ beta
chain with DQB1*03:02, a known high risk haplotype.
Table 1. DRB1-DQA1-DQB1 haplotype frequencies in controls and early-onset type 1 diabetes (T1D)
patients and corresponding odds ratios to develop early-onset T1D.
DRB1* DQA1* DQB1* Controls T1D Patients Odds Ratio (CI) p
n (%) n (%)
01:01 01:01 05:01 3582 (9.2) 32 (6.9) 0.73 (0.51; 1.05) 0.087
01:02 01:01 05:01 471 (1.2) 5 (1.1) 0.89 (0.39; 2.08) 0.795
03:01 05:01 02:01 4089 (10.5) 155 (33.3) 4.27 (3.51; 5.17) <0.001
04:01 03:01 03:02 1801 (4.6) 149 (32.0) 9.73 (7.96; 11.86) <0.001
04:01 03:01 03:01 989 (2.5) 3 (0.6) 0.25 (0.08; 0.71) 0.010
04:02 03:01 03:02 391 (1.0) 12 (2.6) 2.62 (1.46; 4.63) <0.001
04:03 03:01 03:02 271 (0.7) 1 (0.2) 0.31 (0.03; 1.69) 0.214
04:04 03:01 03:02 809 (2.1) 19 (4.1) 2.01 (1.28; 3.17) 0.003
04:05 03:01 02:02 36 (0.1) 3 (0.6) 7.03 (2.26; 21.65) <0.001
04:05 03:01 03:02 111 (0.3) 8 (1.7) 6.13 (2.94; 12.36) <0.001
07:01 02:01 02:02 3408 (8.7) 5 (1.1) 0.11 (0.05; 0.26) <0.001
07:01 02:01 03:03 1411 (3.6) 1 (0.2) 0.06 (0.01; 0.31) <0.001
08:01 04:01/02* 04:02 971 (2.5) 22 (4.7) 1.95 (1.25; 2.97) 0.002
11:01 05:01 03:01 2987 (7.6) 3 (0.6) 0.08 (0.03; 0.22) <0.001
11:04 05:01 03:01 1363 (3.5) 1 (0.2) 0.06 (0.01; 0.32) <0.001
12:01 05:01 03:01 757 (1.9) 4 (0.9) 0.44 (0.17; 1.11) 0.092
13:01 01:03 06:03 2737 (7.0) 8 (1.7) 0.23 (0.11; 0.45) <0.001
13:02 01:02 06:04 1441 (3.7) 12 (2.6) 0.69 (0.39; 1.20) 0.205
13:03 05:01 03:01 542 (1.4) 1 (0.2) 0.15 (0.02; 0.83) 0.031
14:01/54* 01:01 05:03 726 (1.9) 0 (0.0) 0.00 (0; 0.39) 0.003
15:01 01:02 06:02 4634 (11.9) 0 (0.0) 0.00 (0; 0.05) <0.001
16:01 01:02 05:02 1014 (2.6) 13 (2.8) 1.08 (0.61; 1.86) 0.792
others 4547 (11.6) 9 (1.9)
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Table 2. Analysis of the DRB1-DQA1-DQB1 second alleles in heterozygous DRB1*03/x (DR3-DQ2) and
HLA DRB1*04/x (DR4-DQ8) patient and controls, carrying one high-risk allele. Data were separately
analysed for HLA DRB1*03/x (DR3-DQ2) and DRB1*04/x (DR4/DQ8) heterozygous groups.
Patients with DRB1*03/x
DRB1* DQA1* DQB1* Controls T1D Patients Odds Ratio (CI) p
n (%) n (%)
01:01 01:01 05:01 359 (10.5) 11 (29.7) 3.62 (1.76; 7.39) <0.001
07:01 02:01 02:02 332 (9.7) 2 (5.4) 0.53 (0.13; 1.98) 0.575
08:01 04:01/02 04:02 105 (3.1) 5 (13.5) 4.95 (2.05; 12.22) 0.006
09:01 03:02 03:03 23 (0.7) 4 (10.8) 17.95 (6.37; 53.99) <0.001
12:01 05:05 03:01 94 (2.7) 2 (5.4) 2.03 (0.47; 7.78) 0.274
13:01 01:03 06:03 281 (8.2) 2 (5.4) 0.64 (0.15; 2.39) 0.765
13:02 01:02 06:04 142 (4.1) 3 (8.1) 2.04 (0.65; 6.03) 0.200
16:01 01:02 05:02 120 (3.5) 8 (21.6) 7.61 (3.56; 16.52) <0.001
others 1972 (57.5)
Patients with DRB1*04/x (DRB1*04 combining the DRB1*04:01/02/04/05 alleles, see text)
DRB1* DQA1* DQB1* Controls T1D Patients Odds Ratio (CI) p
n (%) n (%)
01:01 01:01 05:01 291 (11.6) 15 (25.0) 2.55 (1.39; 4.53) 0.001
01:02 01:01 05:01 36 (1.4) 2 (3.3) 2.37 (0.55; 9.34) 0.221
04:01 03:02 03:01 44 (1.8) 2 (3.3) 1.94 (0.45; 7.44) 0.291
07:01 02:01 02:02 260 (10.3) 3 (5.0) 0.46 (0.15; 1.35) 0.276
07:01 02:01 03:03 100 (4.0) 1 (1.7) 0.41 (0.04; 2.24) 0.730
08:01 04:01/02 04:02 202 (8.0) 14 (23.3) 3.48 (1.91; 6.38) <0.001
08:04 04:01 04:02 8 (0.3) 1 (1.7) 5.31 (0.47; 35.27) 0.192
11:01 05:05 03:01 254 (10.1) 4 (6.7) 0.64 (0.24; 1.69) 0.515
11:03 05:05 03:01 28 (1.1) 1 (1.7) 1.51 (0.14; 9.12) 0.497
12:01 05:05 03:01 53 (2.1) 1 (1.7) 0.79 (0.08; 4.46) >0.999
13:01 01:03 06:03 209 (8.3) 5 (8.3) 1.00 (0.43; 2.39) >0.999
13:02 01:02 06:04 118 (4.7) 6 (10.0) 2.26 (1.03; 5.30) 0.058
13:03 05:05 03:01 40 (1.6) 1 (1.7) 1.05 (0.10; 6.08) 0.623
16:01 01:02 05:02 90 (3.6) 4 (6.7) 1.92 (0.73; 5.00) 0.278
others 781 (31.1)
3.3. Comparison of Human Leukocyte Antigen Haplotypes between the Study Cohort and Other
Adolescent-Onset T1D and T2D Cohorts
HLA haplotype frequencies in early-onset diabetes patients were further compared with previous
results from the German/Austrian nationwide diabetes DPV registry, analysing older T1D patients
diagnosed before age 20 years (mean age at manifestation 8.3 years; n = 1445) and a cohort with
juvenile-onset of type 2 diabetes (T2D, mean age at diagnosis 13.8 years; n = 109) [34,35]. These cohorts
had been in part HLA-typed serologically in the 1970s and 80s [34], while most patients were
HLA-typed by Polymerase Chain Reaction (PCR) with sequence-specific primers in the individual
laboratories [34,35]. For comparability, the HLA types were subcategorized into three groups.
A moderate to high-risk group (DRB1*03/03, or 03/x, or DRB1*04/04, or 04/x), and one group with
DR x/x (the x haplotype denotes other haplotypes, non-03 or -04) were compared to the highest-risk
genotype (DRB1*03:01-DQA1*05:01-DQB1*02:01/DRB1*04-DQA1*03:01-DQB1*03:02), as described
previously. The prevalence of the highest-risk haplotype was significantly higher in the early-onset
T1D cohort compared to both the other aforementioned later onset T1D and T2D patient cohorts.
Prevalences in early-onset T1D were significantly different from the other cohorts showing more
highest-risk and moderate- to high-risk haplotypes (each p < 0.001), while the percentage of patients
in the moderate to high risk group did not differ between the early-onset T1D and the T2D group
(Figure 2).
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T1D (n = 1445; data fr m [34]) and type 2 diabetes (T2D) patients (n = 109, data from [35]) with a local
control population (n = 19,544, each ** p < 0.001).
3.4. Comparison of Clinical Data of the Highest-Risk Haplotype Combination vs. Ot r Haplotypes
Table 3 shows the comparison of clinical data between patients with the highest-risk genotype
(n = 86/195) and patients with moderate (n = 103) and low risk (n = 6) haplotypes. There were no
differenc s in sex distribution (52.3% vs. 54.4% s. 50% males, p = 0.948) or age at manifestation
(2.8 ± 1.1 vs. 2.8 ± 1.2 vs. 3.2 ± 1.5 years, p = 0.804). The mean age (16.4 ± 3.2 vs. 17.5 ± 3.0 vs.
17.1 ± 2.2 years, p = 0.018) and diabetes duration (13.6 ± 3.0 vs. 14.8 ± 3.0 vs. 14.0 ± 2.1 years,
p = 0.014) at the last year of observation was up to one year shorter in the highest-risk HLA group than
in the other groups. Anthropometric parameters, SMBG, total daily insulin use, insulin dosage per kg
body weight and blo d pr ssure were comparable between those HLA groups. Whil HbA1c levels,
cholesterol levels, creatinin , and urine albumi uria did not diff between the groups, triglyceride
levels were by trend lower in the highest-risk group compared to moderate risk haplotypes (p = 0.051).
Rates of severe hypoglycaemia, hypoglycaemic coma, and hospitalization related to hypoglycaemia or
diabetic ketoacidosis were not significantly different between HLA risk groups. Clinical diagnosis of
celiac disease affected 10.6% in the highest-risk, 5.6% in the moderate risk group and 7.0% in the low
risk HLA group (Table 3). The prevalence of autoimmune thyroiditis was lower with 8.8 vs. 18.3%
in the highest-risk vs. moderate risk group, however not statistically significant. Transglutaminase,
thyroid peroxidase (TPO) or thyroglobulin (TG) autoantibody prevalence did not differ significantly
between groups.
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Cholesterol (mg/dL) 748 174.8 (169.9; 179.8) 926 178.2 (173.6; 182.9) 55 174.9 (156.3; 193.4) 0.608
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Haplotype (n = 103)
Low Risk Haplotype
(n = 6)
n 2 % or mean (SE) n 2 % or mean (SE) n 2 % or mean (SE) p 1
LDL-Cholesterol (mg/dL) 606 96.9 (91.9; 101.9) 732 96.3 (91.7; 101.0) 40 93.8 (75.6; 111.9) 0.942
Triglyceride (mg/dL) 709 98.9 (91.0; 106.9) 874 112.1 (104.8; 119.4) 55 98.4 (69.5; 127.4) 0.051
Creatinine (mg/dL) 718 57.0 (55.3; 58.7) 847 58.5 (57.0; 60.1) 40 55.6 (49.0; 62.3) 0.348
Urine albuminuria (mg/L) 315 11.8 (0.0; 26.0) * 383 16.0 (3.1; 28.9) * 15 1.8 (0.0; 66.0) * 0.852*
Rate of severe hypoglycaemia
(1/100 patient years) 1012 18.5 (12.3; 27.9) 1287 28.7 (19.9; 41.4) 75 6.5 (1.2; 35.6) 0.100
Rate of hypoglycaemic coma








1012 1.7 (0.9; 3.2) 1287 2.7 (1.6; 4.5) 75 1.4 (0.1; 17.3) 0.494
n 3 % or mean (SE) n 3 % or mean (SE) n 3 % or mean (SE) p 1
Microalbuminuria (%) 4 80 36.9 (27.0; 48.1) 95 43.0 (33.3; 53.2) 6 17.0 (3.8; 66.2) 0.497
Macroalbuminuria (%) 4 80 3.5 (1.1; 10.9) 95 4.9 (1.9; 11.9) 6 7.9 (0.4; 63.7) 0.838
Retinopathy (%) 4 82 2.2 (0.5; 9.2) 97 3.8 (1.3; 10.4) 6 8.0 (0.4; 63.4) 0.689
Transglutaminase antibodies (%) 4 66 26.3 (16.8; 38.6) 73 20.4 (12.4; 31.7) 4 11.0 (0.5; 76.5) 0.633
Clinical celiac disease (%) 4 86 10.6 (5.6; 19.3) 103 4.6 (1.9; 10.7) 6 7.1 (0.4; 62.0) 0.231
TPO antibodies (%) 4 72 16.3 (9.3; 27.1) 83 25.0 (16.4; 36.2) 6 5.5 (0.2; 59.0) 0.283
TG antibodies (%) 4 56 22.8 (12.8; 37.2) 71 16.9 (9.3; 26.6) 4 4.9 (0.2; 60.2) 0.489
Clinical thyroiditis (%) 4 86 8.8 (4.4; 17.0) 103 18.3 (11.7; 27.5) 6 5.8 (0.3; 59.7) 0.148
Data are adjusted estimates from mixed linear, mixed Poisson or fixed effects logistic regression adjusting for
sex and diabetes duration. 1 F-Test from linear or Poisson regression for continuous or variables and X2-Test
from logistic regression for variables categorical; 2 Total number of observation years contributed by patients
(varying dependent on performed measurements at clinical visits); 3 Total number of patients (varying dependent
on performed measurements); 4 Only data of the last documented year are used. Diabetic complications and
associated autoimmune diseases are defined cumulatively over the individual observation periods per patient.
* Not adjusted for sex and diabetes duration. SMBG: frequency of self-monitoring of blood glucose; TPO: thyroid
peroxidase; TG: thyroglobulin.
3.5. C-peptide
C-peptide levels were below the detection limit of standard assays (regularly > 30 pmol/L) and
below a clinically relevant threshold (usually defined as > 200 pmol/L). According to the results of the
ultrasensitive assay, 25.0% (20/80) of the patients with the highest-risk genotype, 19.8% (19/96) of the
patients with a moderate risk genotype and 33.3% (2/6) of the patients with low risk haplotypes had
detectable residual C-peptide (p = 0.579). C-peptide levels were comparable in all three risk groups
(means adjusted for gender and diabetes duration from regression analysis: 6.1 ± 1.5 vs. 6.0 ± 1.6 vs.
5.2 ± 4.9 pmol/L, p = 0.982). As there were only two C-peptide levels known in the low risk group, we
included them in the ‘other haplotypes’ column (Figure 3).
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4. Discussion
4.1. Aim and Main Findings
We analysed HLA-DRB1-DQA1-DQB1 haplotype frequencies and clinical data with respect
to MHC class II risk groups in a German cohort of patients with preschool manifestation of
autoimmune diabetes.
4.2. Limitations
We acknowledge the limitations of our investigation: T1D was assumed based on the medical
history, clinical and laboratory parameters, and was not verified by diabetes-specific autoantibody
analyses in all cases. Due to genetic differences between different ethnicities, the results from this
European cohort may not be transferred to other populations. Comparability of C-peptide levels
between individuals may be limited by random, unstimulated measurement of C-peptide levels.
4.3. Highest-Risk Genotype
An earlier clinical onset of T1D is associated with a higher genetic susceptibility [36].
Early-onset T1D was strongly associated with the highest-risk haplotype combination
HLA-DRB1*03:01-DQA1*05:01-DQB1*02:01/DRB1*04-DQA1*03:01-DQB1*03:02, affecting 44.6% of the
patients in our early-onset cohort. In contrast, the frequency of this haplotype combination in the
general Caucasian population is estimated about 2% [37], and was 1.8% in our control population.
Our results are in line with previous reports in several European cohorts on manifestation before
the age of six years, with 33–52% of individuals sharing this haplotype [7,9,14–16,38–40]. Noble
and Valdes noted that the odds ratios for the diabetes risk were much higher for the heterozygote
genotype (OR = 16.6) than for either of the homozygotes (DRB1*03/*03, OR = 6.3; DRB1*04/*04,
OR = 5.7) [40]. This was true also in our cohort (DRB1*03/DRB1*04, OR = 45.14 (34.14; 96.99).
This synergistic effect favouring the DRB1*03/DRB1*04 genotype was explained by the formation of
HLA-DQ8 trans (and DQ2 trans) dimers in heterozygous individuals [41,42], while this has not yet
been demonstrated experimentally.
4.4. Other Haplotypes Conferring Risk for T1D
We found an association with DRB1*01:01-DQA1*01:01-DQB1*05:01 (DR1-DQ5),
DRB1*16:01-DQA1*01:02-DQB1*05:02 (DR16-DQ5), DRB1*08:01-DQA1*04:01/02-DQB1*04:02
(DR8-DQ4) plus the rare DRB1*09:01-DQA1*03:02-DQB1*03:03 in the second alleles, showing
a predominant role of six haplotypes influencing the risk in 231 of 233 (99.1%) cases. Genetic
heterogeneity was low within this early-onset T1D cohort.
For DRB1*08:01-DQA1*04:01/02-DQB1*04:02 a predisposing effect for T1D has been described
previously [39], the positive association of DR16-DQ5 in the heterozygotes is a potentially novel
finding. Thomson et al. had shown in 1988 that an excess of both DR8 and DR1 occurs in
combination with DR4 in individuals lacking the highest-risk heterozygote, while at that time data
on the associated DQ allele were not available and DR16-DQ5 was still subsumed under the DR2
serotype [43]. Other authors did not observe a susceptibility for DRB1*01:01-DQA1*01:01-DQB1*05:01
or DRB1*08:01-DQA1*04:01/02-DQB1*04:02 [7,9,14]. As besides HLA II genes the local upregulation
of HLA I plays a central role in insulitis and β-cell destruction, MCH class I genotyping data would
further our understanding of the underlying genetic risk and should be pursued in future analyses
in parallel.
4.5. Protection
The absence of DR15-DQ6 in our cohort, which is a common haplotype in the general population
(11.9% in the control cohort) clearly shows its protective effect. Strikingly, we also found a lack
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of protective haplotypes in the secondary alleles and in the ‘low-risk’ group. This well-known
phenomenon cannot be easily explained, as mechanisms of protection by HLA class II alleles remain
to be determined. Potential mechanisms include tolerance induction to potentially autoantigenic
peptides by their stable presentation on cell surfaces, the induction of regulatory T-cells, or deletion of
autoreactive T-cells [44–46].
4.6. Peptide Binding to the MHC Antigen
It is known, that different HLA alleles are associated with a different expression of
pancreas-specific autoantibodies. It is likely, but not completely elucidated, that certain MHC II alleles
preferentially bind different pancreatic antigenic peptides. Certain amino acid positions in the variable
region are particularly important regarding the structure of the binding pocket, determining which
potentially pathogenic peptides are presented to the T-cell receptor. Position 57 in the DQ beta-chain
(forming the P9-pocket) and residues 13 and 71 in the DR beta-chain (forming the P4 pocket) play the
most important role in T1D susceptibility [47]. Alanine at position 57 of the DQ beta-chain confers the
highest-risk and is coded by DQB1*02:01/02 and 03:02/04, while aspartic acid in this position conveys
protection [38,46–48]. The peptide targets involved in the pathogenesis of T1D are subject of current
investigation and include preproinsulin and glutamate decarboxylase (GAD) derived peptides, as well
as misfolded or modified proteins [10,48–52]. In celiac disease, also associated with DQB1*02:01 and
DQB1*03:02, it is well documented that pathogenic, e.g., gliadin/avenin/glutenin-derived peptides,
are recognized by CD4+ T-cells only when bound to HLA DQ2 or DQ8 [53].
4.7. The Combination of Alleles Determines the T1D Risk
We would like to point out that it is the combination of HLA-DRB1, DQA1, and DQB1 alleles
that determines the diabetes risk in our cohort. If we had focused on single alleles, we would have
found different risks for T1D for DQB1*02:01 (OR 12.04 (9.97; 14.5), p < 0.001) and DRB1*02:02 (no case
found in our cohort, OR 0.04 (0.01; 0.15), p < 0.001), though DQB1*02:02 and 02:01 have the same amino
acid sequence coded by exon 2, coding for the peptide binding motif of the beta-chain of the HLA
DQ antigen. Therefore, the associated alpha-chain DQA1*05:01 or the associated HLA-DRB1*03:01,
occurring in the linkage disequilibrium with DQB1*02:01, must be responsible for differences in
diabetes risk.
Another example shows a predominant role of the DQ antigen instead: DRB1*04:01 occurs linked
to DQB1*03:01 or 03:02. These two DQ haplotypes confer a completely different risk for T1D (Table 1),
although they both have the same DRB1 and DQA1 alleles (considering that both associated DQA1
alleles are identical in exon 2). In this case, the DRB1 allele is irrelevant for the specificity of peptide
presentation, but the DQB1 plays the pivotal role.
Although both alleles are common in the control population, we did not find the combination
DRB1*07:01-DQA1*01:01-DQB1*02:02/DRB1*11:01-DQA1*05:01-DQB1*03:01 within our cohort. This
haplotype combination could build a similar DQ complex in trans as the high-risk haplotype
DRB1*03:01-DQA1*05:01-DQB1*02:01. We can infer that, in this case, it is not the DQ antigen and its
peptide binding properties, but DRB1*03:01, that accounts for the susceptibility. We do not see the
DQ2 allele as the crucial risk factor for the development of β-cell autoimmunity.
4.8. Clinical Data
One should be aware that we clinically compared patients with the highest-risk haplotype
combination to other still high-risk haplotypes, as more than 95% of all patients in the early-onset
group had at least one high-risk allele. In contrast to other investigations with broader age ranges
analysed [37], we did not observe an age gradient comparing the age groups (0–1, 1–2 years, etc.,
not shown) nor a difference in age at manifestation between the HLA risk-groups. We examined the
associations between HLA-DRB1-DQA1-DQB1 haplotypes and the clinical characteristics of diabetes in
longitudinal data. During a follow-up of an average 12 years of diabetes, we found lower triglyceride
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levels by trend in the highest-risk group, but cannot derive a clinical implication. In addition to that,
we did not detect any clinically-significant differences in clinical, metabolic or laboratory parameters
between the HLA risk groups. Previously-reported differences in blood pressure within three years
after diagnosis were not confirmed in the present study [22].
The frequency of positive thyroid antibodies in the study cohort was comparable to other
studies [54]. Although there is a known association of thyroid autoimmunity with DRB1*03 and
DRB1*04 alleles, in our analysis, the clinical diagnosis of autoimmune thyroid disease was less common
in T1D patients (8.0% vs. 18.3%) with the highest-risk genotype, missing statistical significance [55].
Our data possibly confirm a minor importance of HLA alleles in the pathogenesis of autoimmune
thyroid disease compared to other autoimmune diseases [56].
A previous study reported that patients with positive celiac disease-specific antibodies were
significantly younger at diabetes onset [57]. About 90% of celiac disease cases (without comorbid
T1D) are associated with DQA1*05:01 and DQB1*02:01 (DQ2) and experience a mechanistically-similar
autoimmune process as T1D patients [58]. These alleles may occur in cis configuration in association
with the DRB1*03 haplotype or in trans configuration in a combination with DRB1*07/11/12 positive
haplotypes [59], which are rarely seen in T1D.
Within the group of young T1D patients, HLA genotyping is not distinctive for diagnosis of celiac
disease, as more than 90% of T1D cases have high-risk DQ alleles [58,60,61]. The frequency of celiac
disease and associated celiac autoantibody positivity in those with the highest-risk genotype was not
statistically significant different from others.
4.9. C-peptide
The loss of residual insulin secretion is, next to diabetes duration, related to the age at diabetes
onset [62]. After five years of diabetes, 10% of individuals from the SEARCH for Diabetes in Youth
study had C-peptide levels above a clinically-relevant threshold (>230 pmol/L) [63]. This indicates
that a significant number of β-cells are evading immune attack with implications for future treatment
strategies in T1D [64]. Apart from clinically-relevant C-peptide secretion, any detectable C-peptide is
also of interest as a marker of surviving functional β-cells. New ultrasensitive C-peptide assays with
lower detection limits found residual C-peptides in 10% (serum) to 80% (urine) of T1D individuals,
more than 30 years after disease manifestation [30,63]. So far, the influence of the underlying
autoimmune process in terms of the genetic background of T1D patients on C-peptide preservation
is unknown. With the above-described ultrasensitive assay, random C-peptide was detectable in
23.5% (42/179) of our cases after a mean diabetes duration of 10–20 years. This is lower than that
reported previously for patients with onset at a mean of 17.8 years of age, who showed a detectable
fasting C-peptide in 38% after 11–20 years of diabetes, suggesting a more severe and complete β-cell
destruction in early-onset disease [32]. Within the group of early-onset patients, C-peptide levels did
not differ between the HLA risk groups, thus not indicating a more severe phenotype in the subgroup
of highest-risk patients.
4.10. Clinical Implications
T1D research includes the development of strategies for diagnosing the disease at earlier stages
in its natural history with the aim to introduce safe and effective therapeutic options for disease
prevention [65]. Large-scale screening studies make use of the predictive value of high-risk HLA
DR-DQ haplotypes in newborns (e.g., the ‘Freder1k study in Saxony’ in Germany) to generate large
enough groups at risk for primary prevention or interventional studies. Considering that different
HLA class II genotypes preferentially bind different autoantigenic peptides, the chances of benefit
from a treatment with antigenic peptides (e.g., oral insulin, GAD, Diapep277, etc.) may be, in part,
depending on HLA-DR-DQ genotypes, and this should be addressed in future interventional studies.
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5. Conclusions
We confirmed the predominant role of the highest-risk haplotype combination for diabetes risk in
our early-onset cohort. Genetic heterogeneity was low as far as HLA class II alleles were concerned. Of
note, six haplotypes explained part of the diabetes risk in 231 of 233 cases. The importance of protective
haplotypes for the prevention of early-onset diabetes is demonstrated by the lack of protective alleles
in our cohort, while the mechanism of protection remains elusive. One could hypothesize, that a single
protective allele severely reduces the risk to develop T1D in preschool age. A combination of alleles,
rather than a single allele or a single amino acid residue in an allele determines the HLA risk for T1D.
HLA status was not associated with significant differences in the clinical course or prevalence
of associated autoimmunity in early-onset T1D cases, nor with different levels of residual C-peptide.
After more than 10 years of diabetes duration, one in four individuals showed some residual C-peptide,
detectable with an ultrasensitive assay. While HLA genes are important to determine the risk to
develop early onset T1D, the long-term clinical course in this patient group, independent from the
underlying HLA DR-DQ genotype.
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